

ICD-10 Procedure Coding System (ICD-10-PCS) 2023 Tables Addenda

ICD-10-PCS Tables that have changed this year are shown in table format in the pages below. Click on a bookmark to go to a specific table.

Each table shown in the addenda replaces the table from the previous year.

02L

No change	<i>Section</i> 0 Medical and Surgical			
	<i>Body System</i> 2 Heart and Great Vessels			
	<i>Operation</i> L Occlusion: Completely closing an orifice or the lumen of a tubular body part			
Heading	<i>Body Part</i>	<i>Approach</i>	<i>Device</i>	<i>Qualifier</i>
No change	7 Atrium, Left	0 Open 3 Percutaneous 4 Percutaneous Endoscopic	C Extraluminal Device D Intraluminal Device Z No Device	K Left Atrial Appendage
No change	H Pulmonary Valve P Pulmonary Trunk Q Pulmonary Artery, Right S Pulmonary Vein, Right T Pulmonary Vein, Left V Superior Vena Cava	0 Open 3 Percutaneous 4 Percutaneous Endoscopic	C Extraluminal Device D Intraluminal Device Z No Device	Z No Qualifier
No change	R Pulmonary Artery, Left	0 Open 3 Percutaneous 4 Percutaneous Endoscopic	C Extraluminal Device D Intraluminal Device Z No Device	T Ductus Arteriosus Z No Qualifier
FY2023	W Thoracic Aorta, Descending	0 Open 3 Percutaneous	D Intraluminal Device	J Temporary

04L

No change	Section 0 Medical and Surgical			
	Body System 4 Lower Arteries			
	Operation L Occlusion: Completely closing an orifice or the lumen of a tubular body part			
Heading	Body Part	Approach	Device	Qualifier
FY2023	0 Abdominal Aorta	0 Open 3 Percutaneous	C Extraluminal Device Z No Device	Z No Qualifier
FY2023	0 Abdominal Aorta	0 Open 3 Percutaneous	D Intraluminal Device	J Temporary Z No Qualifier
FY2023	0 Abdominal Aorta	4 Percutaneous Endoscopic	C Extraluminal Device D Intraluminal Device Z No Device	Z No Qualifier
No change	1 Celiac Artery 2 Gastric Artery 3 Hepatic Artery 4 Splenic Artery 5 Superior Mesenteric Artery 6 Colic Artery, Right 7 Colic Artery, Left 8 Colic Artery, Middle 9 Renal Artery, Right A Renal Artery, Left B Inferior Mesenteric Artery C Common Iliac Artery, Right D Common Iliac Artery, Left H External Iliac Artery, Right J External Iliac Artery, Left K Femoral Artery, Right L Femoral Artery, Left M Popliteal Artery, Right N Popliteal Artery, Left P Anterior Tibial Artery, Right Q Anterior Tibial Artery, Left R Posterior Tibial Artery, Right S Posterior Tibial Artery, Left T Peroneal Artery, Right U Peroneal Artery, Left V Foot Artery, Right W Foot Artery, Left Y Lower Artery	0 Open 3 Percutaneous 4 Percutaneous Endoscopic	C Extraluminal Device D Intraluminal Device Z No Device	Z No Qualifier
No change	E Internal Iliac Artery, Right	0 Open 3 Percutaneous 4 Percutaneous Endoscopic	C Extraluminal Device D Intraluminal Device Z No Device	T Uterine Artery, Right V Prostatic Artery, Right Z No Qualifier
No change	F Internal Iliac Artery, Left	0 Open 3 Percutaneous 4 Percutaneous Endoscopic	C Extraluminal Device D Intraluminal Device Z No Device	U Uterine Artery, Left W Prostatic Artery, Left Z No Qualifier

0P5

FY2023	<i>Section</i>	0	Medical and Surgical	
	<i>Body System</i>	P	Upper Bones	
	<i>Operation</i>	5	Destruction: Physical eradication of all or a portion of a body part by the direct use of energy, force, or a destructive agent	
Heading	<i>Body Part</i>	<i>Approach</i>	<i>Device</i>	<i>Qualifier</i>
FY2023	0 Sternum 1 Ribs, 1 to 2 2 Ribs, 3 or More 5 Scapula, Right 6 Scapula, Left 7 Glenoid Cavity, Right 8 Glenoid Cavity, Left 9 Clavicle, Right B Clavicle, Left C Humeral Head, Right D Humeral Head, Left F Humeral Shaft, Right G Humeral Shaft, Left H Radius, Right J Radius, Left K Ulna, Right L Ulna, Left M Carpal, Right N Carpal, Left P Metacarpal, Right Q Metacarpal, Left R Thumb Phalanx, Right S Thumb Phalanx, Left T Finger Phalanx, Right V Finger Phalanx, Left	0 Open 3 Percutaneous 4 Percutaneous Endoscopic	Z No Device	Z No Qualifier
FY2023	3 Cervical Vertebra 4 Thoracic Vertebra	0 Open 3 Percutaneous 4 Percutaneous Endoscopic	Z No Device	3 Laser Interstitial Thermal Therapy Z No Qualifier

0Q5

FY2023	Section 0 Medical and Surgical			
	Body System Q Lower Bones			
	Operation 5 Destruction: Physical eradication of all or a portion of a body part by the direct use of energy, force, or a destructive agent			
Heading	Body Part	Approach	Device	Qualifier
FY2023	0 Lumbar Vertebra	0 Open	Z No Device	3 Laser Interstitial Thermal Therapy
	1 Sacrum	3 Percutaneous 4 Percutaneous Endoscopic		Z No Qualifier
FY2023	2 Pelvic Bone, Right	0 Open	Z No Device	Z No Qualifier
	3 Pelvic Bone, Left	3 Percutaneous		
	4 Acetabulum, Right	4 Percutaneous Endoscopic		
	5 Acetabulum, Left			
	6 Upper Femur, Right			
	7 Upper Femur, Left			
	8 Femoral Shaft, Right			
	9 Femoral Shaft, Left			
	B Lower Femur, Right			
	C Lower Femur, Left			
	D Patella, Right			
	F Patella, Left			
	G Tibia, Right			
	H Tibia, Left			
	J Fibula, Right			
	K Fibula, Left			
	L Tarsal, Right			
	M Tarsal, Left			
	N Metatarsal, Right			
	P Metatarsal, Left			
	Q Toe Phalanx, Right			
	R Toe Phalanx, Left			
	S Coccyx			

302

No change	Section 3 Administration				
	Body System 0 Circulatory				
	Operation 2 Transfusion: Putting in blood or blood products				
Heading	Body System / Region		Approach	Substance	Qualifier
No change	3 Peripheral Vein 4 Central Vein		3 Percutaneous	A Stem Cells, Embryonic	Z No Qualifier
No change	3 Peripheral Vein 4 Central Vein		3 Percutaneous	C Hematopoietic Stem/Progenitor Cells, Genetically Modified	0 Autologous
No change	3 Peripheral Vein 4 Central Vein		3 Percutaneous	D Pathogen Reduced Cryoprecipitated Fibrinogen Complex	1 Nonautologous
No change	3 Peripheral Vein 4 Central Vein		3 Percutaneous	G Bone Marrow X Stem Cells, Cord Blood Y Stem Cells, Hematopoietic	0 Autologous 2 Allogeneic, Related 3 Allogeneic, Unrelated 4 Allogeneic, Unspecified
No change	3 Peripheral Vein 4 Central Vein		3 Percutaneous	H Whole Blood J Serum Albumin K Frozen Plasma L Fresh Plasma M Plasma Cryoprecipitate N Red Blood Cells P Frozen Red Cells Q White Cells R Platelets S Globulin T Fibrinogen V Antihemophilic Factors W Factor IX	0 Autologous 1 Nonautologous
No change	3 Peripheral Vein 4 Central Vein		3 Percutaneous	U Stem Cells, T-cell Depleted Hematopoietic	2 Allogeneic, Related 3 Allogeneic, Unrelated 4 Allogeneic, Unspecified
No change	7 Products of Conception, Circulatory		3 Percutaneous 7 Via Natural or Artificial Opening	H Whole Blood J Serum Albumin K Frozen Plasma L Fresh Plasma M Plasma Cryoprecipitate N Red Blood Cells P Frozen Red Cells Q White Cells R Platelets S Globulin T Fibrinogen V Antihemophilic Factors W Factor IX	1 Nonautologous
No change	8 Vein		3 Percutaneous	B 4-Factor Prothrombin Complex Concentrate	1 Nonautologous
FY2023	A Bone Marrow		3 Percutaneous	H Whole Blood J Serum Albumin K Frozen Plasma L Fresh Plasma N Red Blood Cells P Frozen Red Cells R Platelets	0 Autologous 1 Nonautologous

XW0

No change	Section	X	New Technology	
No change	Body System	W	Anatomical Regions	
	Operation	0	Introduction: Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products	
Heading	Body Part	Approach	Device / Substance / Technology	Qualifier
No change	0 Skin	X External	2 Bromelain-enriched Proteolytic Enzyme	7 New Technology Group 7
No change	1 Subcutaneous Tissue	3 Percutaneous	1 Daratumumab and Hyaluronidase-fihj 4 Teclistamab Antineoplastic	8 New Technology Group 8
No change	1 Subcutaneous Tissue	3 Percutaneous	9 Satralizumab-mwge	7 New Technology Group 7
No change	1 Subcutaneous Tissue	3 Percutaneous	F Other New Technology Therapeutic Substance	5 New Technology Group 5
FY2023	1 Subcutaneous Tissue	3 Percutaneous	G REGN-COV2 Monoclonal Antibody H Other New Technology Monoclonal Antibody K Lerolimab Monoclonal Antibody S COVID-19 Vaccine Dose 1 T COVID-19 Vaccine Dose 2 U COVID-19 Vaccine	6 New Technology Group 6
No change	1 Subcutaneous Tissue	3 Percutaneous	V COVID-19 Vaccine Dose 3	7 New Technology Group 7
No change	1 Subcutaneous Tissue	3 Percutaneous	W Caplacizumab	5 New Technology Group 5
No change	1 Subcutaneous Tissue	3 Percutaneous	W COVID-19 Vaccine Booster	7 New Technology Group 7
No change	1 Subcutaneous Tissue	X External	2 Bromelain-enriched Proteolytic Enzyme	7 New Technology Group 7
No change	2 Muscle	0 Open	D Engineered Allogeneic Thymus Tissue	8 New Technology Group 8
No change	2 Muscle	3 Percutaneous	S COVID-19 Vaccine Dose 1 T COVID-19 Vaccine Dose 2 U COVID-19 Vaccine	6 New Technology Group 6
No change	2 Muscle	3 Percutaneous	V COVID-19 Vaccine Dose 3 W COVID-19 Vaccine Booster X Tixagevimab and Cilgavimab Monoclonal Antibody Y Other New Technology Monoclonal Antibody	7 New Technology Group 7
No change	3 Peripheral Vein	3 Percutaneous	0 Brexanolone	6 New Technology Group 6
No change	3 Peripheral Vein	3 Percutaneous	0 Spesolimab Monoclonal Antibody	8 New Technology Group 8
No change	3 Peripheral Vein	3 Percutaneous	2 Nerinitide 3 Durvalumab Antineoplastic	6 New Technology Group 6
No change	3 Peripheral Vein	3 Percutaneous	5 Narsoplimab Monoclonal Antibody	7 New Technology Group 7
No change	3 Peripheral Vein	3 Percutaneous	5 Mosunetuzumab Antineoplastic	8 New Technology Group 8
No change	3 Peripheral Vein	3 Percutaneous	6 Lefamulin Anti-infective	6 New Technology Group 6
No change	3 Peripheral Vein	3 Percutaneous	6 Terlipressin	7 New Technology Group 7

No change	3 Peripheral Vein	3 Percutaneous	6 Afamitresgene Autoleucel Immunotherapy	8 New Technology Group 8
No change	3 Peripheral Vein	3 Percutaneous	7 Coagulation Factor Xa, Inactivated	2 New Technology Group 2
No change	3 Peripheral Vein	3 Percutaneous	7 Trilaciclib	7 New Technology Group 7
No change	3 Peripheral Vein	3 Percutaneous	7 Tabelecleucel Immunotherapy	8 New Technology Group 8
No change	3 Peripheral Vein	3 Percutaneous	8 Lurbinectedin	7 New Technology Group 7
No change	3 Peripheral Vein	3 Percutaneous	8 Treosulfan	8 New Technology Group 8
No change	3 Peripheral Vein	3 Percutaneous	9 Ceftolozane/Tazobactam Anti-infective	6 New Technology Group 6
No change	3 Peripheral Vein	3 Percutaneous	9 Inebilizumab-cdon	8 New Technology Group 8
No change	3 Peripheral Vein	3 Percutaneous	A Cefiderocol Anti-infective	6 New Technology Group 6
No change	3 Peripheral Vein	3 Percutaneous	A Ciltacabtagene Autoleucel	7 New Technology Group 7
No change	3 Peripheral Vein	3 Percutaneous	B Cytarabine and Daunorubicin Liposome Antineoplastic	3 New Technology Group 3
No change	3 Peripheral Vein	3 Percutaneous	B Omadacycline Anti-infective	6 New Technology Group 6
No change	3 Peripheral Vein	3 Percutaneous	B Amivantamab Monoclonal Antibody	7 New Technology Group 7
No change	3 Peripheral Vein	3 Percutaneous	C Eculizumab	6 New Technology Group 6
No change	3 Peripheral Vein	3 Percutaneous	C Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Autologous	7 New Technology Group 7
No change	3 Peripheral Vein	3 Percutaneous	D Atezolizumab Antineoplastic	6 New Technology Group 6
No change	3 Peripheral Vein	3 Percutaneous	E Remdesivir Anti-infective	5 New Technology Group 5
No change	3 Peripheral Vein	3 Percutaneous	E Etesevimab Monoclonal Antibody	6 New Technology Group 6
No change	3 Peripheral Vein	3 Percutaneous	F Other New Technology Therapeutic Substance	3 New Technology Group 3
No change	3 Peripheral Vein	3 Percutaneous	F Other New Technology Therapeutic Substance	5 New Technology Group 5
No change	3 Peripheral Vein	3 Percutaneous	F Bamlanivimab Monoclonal Antibody	6 New Technology Group 6
No change	3 Peripheral Vein	3 Percutaneous	G Plazomicin Anti-infective	4 New Technology Group 4
No change	3 Peripheral Vein	3 Percutaneous	G Sarilumab	5 New Technology Group 5
No change	3 Peripheral Vein	3 Percutaneous	G REGN-COV2 Monoclonal Antibody	6 New Technology Group 6
No change	3 Peripheral Vein	3 Percutaneous	G Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Allogeneic	7 New Technology Group 7
No change	3 Peripheral Vein	3 Percutaneous	H Synthetic Human Angiotensin II	4 New Technology Group 4
No change	3 Peripheral Vein	3 Percutaneous	H Tocilizumab	5 New Technology Group 5
No change	3 Peripheral Vein	3 Percutaneous	H Other New Technology Monoclonal Antibody	6 New Technology Group 6
No change	3 Peripheral Vein	3 Percutaneous	H Axicabtagene Ciloleucel Immunotherapy J Tisagenlecleucel Immunotherapy	7 New Technology Group 7
No change	3 Peripheral Vein	3 Percutaneous	K Fosfomycin Anti-infective	5 New Technology Group 5
No change	3 Peripheral Vein	3 Percutaneous	K Idecabtagene Vicleucel Immunotherapy	7 New Technology Group 7
No change	3 Peripheral Vein	3 Percutaneous	L CD24Fc Immunomodulator	6 New Technology Group 6

No change	3 Peripheral Vein	3 Percutaneous	L Lifileucel Immunotherapy M Brexucabtagene Autoleucel Immunotherapy	7 New Technology Group 7
No change	3 Peripheral Vein	3 Percutaneous	N Meropenem-vaborbactam Anti-infective	5 New Technology Group 5
No change	3 Peripheral Vein	3 Percutaneous	N Lisocabtagene Maraleucel Immunotherapy	7 New Technology Group 7
No change	3 Peripheral Vein	3 Percutaneous	Q Tagraxofusp-erzs Antineoplastic S Iobenguane I-131 Antineoplastic U Imipenem-cilastatin-relebactam Anti-infective W Caplacizumab	5 New Technology Group 5
No change	4 Central Vein	3 Percutaneous	0 Brexanolone	6 New Technology Group 6
No change	4 Central Vein	3 Percutaneous	0 Spesolimab Monoclonal Antibody	8 New Technology Group 8
No change	4 Central Vein	3 Percutaneous	2 Nerinitide 3 Durvalumab Antineoplastic	6 New Technology Group 6
No change	4 Central Vein	3 Percutaneous	5 Narsoplimab Monoclonal Antibody	7 New Technology Group 7
No change	4 Central Vein	3 Percutaneous	5 Mosunetuzumab Antineoplastic	8 New Technology Group 8
No change	4 Central Vein	3 Percutaneous	6 Lefamulin Anti-infective	6 New Technology Group 6
No change	4 Central Vein	3 Percutaneous	6 Terlipressin	7 New Technology Group 7
No change	4 Central Vein	3 Percutaneous	6 Afamitresgene Autoleucel Immunotherapy	8 New Technology Group 8
No change	4 Central Vein	3 Percutaneous	7 Coagulation Factor Xa, Inactivated	2 New Technology Group 2
No change	4 Central Vein	3 Percutaneous	7 Trilaciclib	7 New Technology Group 7
No change	4 Central Vein	3 Percutaneous	7 Tabelecleucel Immunotherapy	8 New Technology Group 8
No change	4 Central Vein	3 Percutaneous	8 Lurbinectedin	7 New Technology Group 7
No change	4 Central Vein	3 Percutaneous	8 Treosulfan	8 New Technology Group 8
No change	4 Central Vein	3 Percutaneous	9 Ceftolozane/Tazobactam Anti-infective	6 New Technology Group 6
No change	4 Central Vein	3 Percutaneous	9 Inebilizumab-cdon	8 New Technology Group 8
No change	4 Central Vein	3 Percutaneous	A Cefiderocol Anti-infective	6 New Technology Group 6
No change	4 Central Vein	3 Percutaneous	A Ciltacabtagene Autoleucel	7 New Technology Group 7
No change	4 Central Vein	3 Percutaneous	B Cytarabine and Daunorubicin Liposome Antineoplastic	3 New Technology Group 3
No change	4 Central Vein	3 Percutaneous	B Omadacycline Anti-infective	6 New Technology Group 6
No change	4 Central Vein	3 Percutaneous	B Amivantamab Monoclonal Antibody	7 New Technology Group 7
No change	4 Central Vein	3 Percutaneous	C Eculizumab	6 New Technology Group 6
No change	4 Central Vein	3 Percutaneous	C Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Autologous	7 New Technology Group 7
No change	4 Central Vein	3 Percutaneous	D Atezolizumab Antineoplastic	6 New Technology Group 6
No change	4 Central Vein	3 Percutaneous	E Remdesivir Anti-infective	5 New Technology Group 5
No change	4 Central Vein	3 Percutaneous	E Etesevimab Monoclonal Antibody	6 New Technology Group 6
No change	4 Central Vein	3 Percutaneous	F Other New Technology Therapeutic Substance	3 New Technology Group 3
No change	4 Central Vein	3 Percutaneous	F Other New Technology Therapeutic Substance	5 New Technology Group 5

No change	4 Central Vein	3 Percutaneous	F Bamlanivimab Monoclonal Antibody	6 New Technology Group 6
No change	4 Central Vein	3 Percutaneous	G Plazomicin Anti-infective	4 New Technology Group 4
No change	4 Central Vein	3 Percutaneous	G Sarilumab	5 New Technology Group 5
No change	4 Central Vein	3 Percutaneous	G REGN-COV2 Monoclonal Antibody	6 New Technology Group 6
No change	4 Central Vein	3 Percutaneous	G Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Allogeneic	7 New Technology Group 7
No change	4 Central Vein	3 Percutaneous	H Synthetic Human Angiotensin II	4 New Technology Group 4
No change	4 Central Vein	3 Percutaneous	H Tocilizumab	5 New Technology Group 5
No change	4 Central Vein	3 Percutaneous	H Other New Technology Monoclonal Antibody	6 New Technology Group 6
No change	4 Central Vein	3 Percutaneous	H Axicabtagene Ciloleucel Immunotherapy J Tisagenlecleucel Immunotherapy	7 New Technology Group 7
No change	4 Central Vein	3 Percutaneous	K Fosfomycin Anti-infective	5 New Technology Group 5
No change	4 Central Vein	3 Percutaneous	K Idecabtagene Vicleucel Immunotherapy	7 New Technology Group 7
No change	4 Central Vein	3 Percutaneous	L CD24Fc Immunomodulator	6 New Technology Group 6
No change	4 Central Vein	3 Percutaneous	L Lifleucel Immunotherapy M Brexucabtagene Autoleucel Immunotherapy	7 New Technology Group 7
No change	4 Central Vein	3 Percutaneous	N Meropenem-vaborbactam Anti-infective	5 New Technology Group 5
No change	4 Central Vein	3 Percutaneous	N Lisocabtagene Maraleucel Immunotherapy	7 New Technology Group 7
No change	4 Central Vein	3 Percutaneous	Q Tagraxofusp-erzs Antineoplastic S Iobenguane I-131 Antineoplastic U Imipenem-cilastatin-relebactam Anti-infective W Caplacizumab	5 New Technology Group 5
No change	9 Nose	7 Via Natural or Artificial Opening	M Esketamine Hydrochloride	5 New Technology Group 5
No change	D Mouth and Pharynx	X External	3 Maribavir Anti-infective	8 New Technology Group 8
No change	D Mouth and Pharynx	X External	6 Lefamulin Anti-infective	6 New Technology Group 6
No change	D Mouth and Pharynx	X External	8 Uridine Triacetate	2 New Technology Group 2
FY2023	D Mouth and Pharynx	X External	F Other New Technology Therapeutic Substance J Apalutamide Antineoplastic	5 New Technology Group 5
FY2023	D Mouth and Pharynx	X External	K Sabizabulin	8 New Technology Group 8
FY2023	D Mouth and Pharynx	X External	L Erdafitinib Antineoplastic	5 New Technology Group 5
No change	D Mouth and Pharynx	X External	M Baricitinib	6 New Technology Group 6
No change	D Mouth and Pharynx	X External	R Venetoclax Antineoplastic	5 New Technology Group 5
No change	D Mouth and Pharynx	X External	R Fostamatinib	7 New Technology Group 7
No change	D Mouth and Pharynx	X External	T Ruxolitinib V Gilteritinib Antineoplastic	5 New Technology Group 5
FY2023	G Upper GI	7 Via Natural or Artificial Opening	3 Maribavir Anti-infective K Sabizabulin	8 New Technology Group 8
No change	G Upper GI	7 Via Natural or Artificial Opening	M Baricitinib	6 New Technology Group 6
No change	G Upper GI	7 Via Natural or Artificial Opening	R Fostamatinib	7 New Technology Group 7

No change	G Upper GI	8 Via Natural or Artificial Opening Endoscopic	8 Mineral-based Topical Hemostatic Agent	6 New Technology Group 6
FY2023	H Lower GI	7 Via Natural or Artificial Opening	3 Maribavir Anti-infective K Sabizabulin	8 New Technology Group 8
No change	H Lower GI	7 Via Natural or Artificial Opening	M Baricitinib	6 New Technology Group 6
No change	H Lower GI	7 Via Natural or Artificial Opening	R Fostamatinib	7 New Technology Group 7
No change	H Lower GI	7 Via Natural or Artificial Opening	X Broad Consortium Microbiota-based Live Biotherapeutic Suspension	8 New Technology Group 8
No change	H Lower GI	8 Via Natural or Artificial Opening Endoscopic	8 Mineral-based Topical Hemostatic Agent	6 New Technology Group 6
No change	Q Cranial Cavity and Brain	3 Percutaneous	1 Eladocagene exuparvovec	6 New Technology Group 6
No change	V Bones	0 Open	P Antibiotic-eluting Bone Void Filler	7 New Technology Group 7

XW1

No change	Section X New Technology			
	Body System W Anatomical Regions			
	Operation 1 Transfusion: Putting in blood or blood products			
Heading	Body Part	Approach	Device / Substance / Technology	Qualifier
No change	3 Peripheral Vein	3 Percutaneous	2 Plasma, Convalescent (Nonautologous)	5 New Technology Group 5
No change	3 Peripheral Vein	3 Percutaneous	B Betibeglogene Autotemcel C Omidubicel	8 New Technology Group 8
No change	3 Peripheral Vein	3 Percutaneous	D High-Dose Intravenous Immune Globulin E Hyperimmune Globulin	7 New Technology Group 7
FY2023	3 Peripheral Vein	3 Percutaneous	F OTL-103 G OTL-200 J Exagamglogene Autotemcel	8 New Technology Group 8
No change	4 Central Vein	3 Percutaneous	2 Plasma, Convalescent (Nonautologous)	5 New Technology Group 5
No change	4 Central Vein	3 Percutaneous	B Betibeglogene Autotemcel C Omidubicel	8 New Technology Group 8
No change	4 Central Vein	3 Percutaneous	D High-Dose Intravenous Immune Globulin E Hyperimmune Globulin	7 New Technology Group 7
FY2023	4 Central Vein	3 Percutaneous	F OTL-103 G OTL-200 J Exagamglogene Autotemcel	8 New Technology Group 8